Stifel upgraded RXO Inc. to Buy from Hold with a $22 price target. The firm sees a more favorable setup emerging into the balance of 2026, with the company positioned at the intersection of improving brokerage fundamentals and healthy idiosyncratic levers, the analyst tells investors in a research note. Stifel adds that while RXO's Q1 results were soft, the firm believes the underlying building blocks of recovery are increasingly in place, with stronger pricing discipline and incremental margin expansion looming later this year,
